<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959465</url>
  </required_header>
  <id_info>
    <org_study_id>820902</org_study_id>
    <secondary_id>EUDRACT Number 2009-013394-17</secondary_id>
    <nct_id>NCT00959465</nct_id>
  </id_info>
  <brief_title>A/H1N1 Immunogenicity and Safety in Adults</brief_title>
  <official_title>An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to obtain immunogenicity and safety data at different dose levels
      of an investigational H1N1 pandemic influenza vaccine in healthy adults 18 years of age and
      older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects achieving antibody levels to A/H1N1/California/07/2009 virus that meet the definition of seroprotection and seroconversion at 21 days after the second vaccination</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Influenza</condition>
  <condition>Pandemic Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1/Dose Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1/Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2/Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)</intervention_name>
    <description>Two injections at a 21-day interval (Days 1 and 22)</description>
    <arm_group_label>Cohort 1/Dose Level A</arm_group_label>
    <arm_group_label>Cohort 1/Dose B</arm_group_label>
    <arm_group_label>Cohort 2/Dose C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18 to 59 years old (age stratum A) or 60 years of age or older (age stratum
             B) at the time of screening

          -  Subject has an understanding of the study, agrees to its provisions, and gives written
             informed consent prior to study entry

          -  Subject is generally healthy, as determined by the investigator's clinical judgment
             through collection of medical history and the performance of a physical examination

          -  Subject is physically and mentally capable of participating in the study and willing
             to adhere to study procedures to include completion of all elements of the study diary

          -  If female of childbearing potential, subject has a negative urine pregnancy test
             result within 24 hours prior to the scheduled first vaccination and agrees to employ
             adequate birth control measures for the duration of the study

        Exclusion Criteria:

          -  Subject has participated in another clinical study involving an investigational drug,
             biological product or device within 30 days prior to study enrollment or is scheduled
             to participate in another clinical study involving an investigational drug, biological
             or device during the course of this study

          -  Subject has a history of exposure to A/H1N1/California/07/2009 virus or a history of
             vaccination with A/H1N1/California/07/2009 antigen or a closely related influenza
             virus antigen

          -  Subject has inherited or acquired immune deficiency

          -  Subject currently has or has a recent history of significant neurological,
             cardiovascular or pulmonary (including asthma), hepatic, metabolic, rheumatic,
             autoimmune, hematological or renal disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Aichinger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanatorium Leech</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Institute for Specific Prophylaxis and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Regner Schmitt</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Gerald Aichinger, MD; Study Medical Director</name_title>
    <organization>Baxter Healthcare Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

